利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

85 条记录 (耗时 0.035 秒)

    Pneumococcal vaccines formulated with interleukin-12
    1.
    发明授权
    Pneumococcal vaccines formulated with interleukin-12 失效
    用白细胞介素-12配制的肺炎球菌疫苗

    公开(公告)号：US06709658B1

    公开(公告)日：2004-03-23

    申请号：US09248195

    申请日：1999-02-10

    申请人： Vincent J. LaPosta ,  John H. Eldridge

    发明人： Vincent J. LaPosta ,  John H. Eldridge

    IPC分类号： A61K39385

    CPC分类号： A61K39/095 ,  A61K39/092 ,  A61K2039/55505 ,  A61K2039/55538 ,  A61K2039/6037 ,  Y10S514/885

    摘要： This invention pertains to vaccine compositions comprising a mixture of antigen, such as a pneumococcal or meningococcal antigen, and interleukin IL-12, which may be adsorbed onto a mineral in suspension. The pneumococcal or meningococcal antigen may be conjugated to a carrier molecule. These vaccine compositions modulate the protective immune response to the antigen.

    摘要翻译： 本发明涉及包含抗原例如肺炎球菌或脑膜炎球菌抗原的混合物和白介素IL-12的疫苗组合物，白细胞介素IL-12可被吸附在悬浮液中的矿物质上。 肺炎球菌或脑膜炎球菌抗原可以与载体分子缀合。 这些疫苗组合物调节对抗原的保护性免疫应答。

    Neisseria meningitidis serogroup B Glycoconjugates
    4.
    发明授权
    Neisseria meningitidis serogroup B Glycoconjugates 失效
    脑膜炎奈瑟氏球菌血清群B糖缀合物

    公开(公告)号：US06638513B2

    公开(公告)日：2003-10-28

    申请号：US08908262

    申请日：1997-08-07

    申请人： Robert Seid

    发明人： Robert Seid

    IPC分类号： A61K39385

    CPC分类号： A61K39/095 ,  A61K2039/6037 ,  Y10S424/831 ,  Y10S424/832 ,  Y10S977/917

    摘要： The present invention pertains generally to Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (MenB OS derivative) in which sialic acid residue N-acetyl groups are replaced with N-acyl groups. The invention also pertains to vaccine formulations containing the glycoconjugates, methods of making the vaccine formulations, and methods of using the vaccine formulations to treat or prevent Neisseria meningitidis serogroup B or E. coli K1 disease in a mammalian subject.

    摘要翻译： 本发明一般涉及脑膜炎奈瑟氏球菌血清群B糖缀合物。 更具体地说，本发明涉及由唾液酸残基N-乙酰基被N-酰基取代的脑膜炎奈瑟氏球菌血清群B荚膜寡糖衍生物（MenB OS衍生物）形成的糖缀合物。 本发明还涉及含有糖缀合物的疫苗制剂，制备疫苗制剂的方法，以及使用疫苗制剂在哺乳动物受试者中治疗或预防脑膜炎奈瑟氏球菌血清群B或大肠杆菌K1疾病的方法。

    Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
    6.
    发明授权
    Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections 有权
    伴侣和粘附素蛋白; 疫苗，诊断和治疗感染的方法

    公开(公告)号：US06500434B1

    公开(公告)日：2002-12-31

    申请号：US09298494

    申请日：1999-04-23

    申请人： Solomon Langermann ,  Scott J. Hultgren ,  Jerome S. Pinkner ,  Christine Gale Auguste

    发明人： Solomon Langermann ,  Scott J. Hultgren ,  Jerome S. Pinkner ,  Christine Gale Auguste

    IPC分类号： A61K39385

    CPC分类号： A61K39/0258 ,  Y02A50/474

    摘要： The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species with heteropolymeric protein complexes as a mechanism for stimulating production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein complexes that may be used as diagnostics and/or as protective/treatment agents for pathogenic bacterial species. A novel vector for expressing the FimC-H complex at optimal levels is also disclosed.

    摘要翻译： 本发明提供用于给予人和非人动物以刺激免疫应答的细菌免疫原性试剂。 它特别涉及用异源蛋白复合物对哺乳动物物种进行疫苗接种，作为刺激保护疫苗接受者免受病原菌种感染的抗体产生的机制。 在另一方面，本发明提供了抗这种蛋白质和蛋白质复合物的抗体，其可以用作诊断和/或作为病原菌种的保护/治疗剂。 还公开了用于以最佳水平表达FimC-H复合物的新载体。

    Stabilized conjugates of uncomplexed subunits of multimeric proteins
    7.
    发明授权
    Stabilized conjugates of uncomplexed subunits of multimeric proteins 有权
    多聚体蛋白的未复合亚单位的稳定缀合物

    公开(公告)号：US06491923B1

    公开(公告)日：2002-12-10

    申请号：US09565286

    申请日：2000-05-02

    申请人： Kirti I. Davé ,  Janos Botyanszki ,  Eva Sintar

    发明人： Kirti I. Davé ,  Janos Botyanszki ,  Eva Sintar

    IPC分类号： A61K39385

    CPC分类号： C07K14/4716 ,  A61K47/60 ,  G01N2333/4712 ,  Y10S514/97 ,  Y10S530/81 ,  Y10S530/815 ,  Y10S530/841

    摘要： The present invention provides methods for preparing, and compositions comprising, stabilized protein-polymer conjugates. More particularly, the present invention relates to the stabilization of individual subunits of multisubunit protein complexes by conjugation to polymers. Such conjugation acts to stabilize the individual subunit in its native conformation in liquid medium, which in turn acts to stabilize its biological activity.

    摘要翻译： 本发明提供了制备方法和包含稳定的蛋白质 - 聚合物共轭物的组合物。 更具体地，本发明涉及通过与聚合物共轭来稳定多亚基蛋白复合物的单个亚单位。 这种共轭作用用于在液体培养基中稳定其天然构象中的单个亚基，其反过来起稳定其生物活性的作用。

    Prevention of primary and metastatic neoplastic diseases with hsp70-peptide complexes
    8.
    发明授权
    Prevention of primary and metastatic neoplastic diseases with hsp70-peptide complexes 失效
    用hsp70肽复合物预防原发性和转移性肿瘤疾病

    公开(公告)号：US06455048B1

    公开(公告)日：2002-09-24

    申请号：US09440173

    申请日：1999-11-15

    申请人： Pramod K. Srivastava ,  Rajiv Y. Chandawarkar

    发明人： Pramod K. Srivastava ,  Rajiv Y. Chandawarkar

    IPC分类号： A61K39385

    CPC分类号： A61K39/0011 ,  A61K2039/6043 ,  A61K2039/622 ,  Y02A50/466

    摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.1 to 9.0 micrograms for complexes comprising hsp70, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96.

    摘要翻译： 本发明涉及引发免疫应答和预防和治疗原发性和转移性肿瘤性疾病和传染病的方法和组合物。 本发明的方法包括施用包含有效量的复合物的组合物，其中复合物基本上由非共价结合于抗原分子的热休克蛋白（hsp）组成。 任选地，所述方法还包括施用用非共价结合于抗原分子的hsps复合物致敏的抗原呈递细胞。 本文所用的“抗原分子”是指hsps与体内内源性相关的肽以及外源性抗原/免疫原（即hsps在体内不复合）或其抗原/免疫原性片段及其衍生物。 在优选的实施方案中，复合物是个体自体的。 在一个具体实施方案中，对于包含hsp70,5-449微克对于hsp90和对于gp96为0.1至9.0微克的复合物，复合物的有效量在0.1至9.0微克范围内。

    Pharmacological composition having blood pressure reductive activity
    9.
    发明授权
    Pharmacological composition having blood pressure reductive activity 失效
    具有血压降低活性的药理组合物

    公开(公告)号：US06419930B2

    公开(公告)日：2002-07-16

    申请号：US09820997

    申请日：2001-03-30

    申请人： Taku Sato ,  Nobuhito Shiragaki ,  Tomoe Kawatsu ,  Toshihiko Hori

    发明人： Taku Sato ,  Nobuhito Shiragaki ,  Tomoe Kawatsu ,  Toshihiko Hori

    IPC分类号： A61K39385

    CPC分类号： A61K36/07

    摘要： A pharmacological composition including a component having pressure reductive activity obtained from Mycoleptodonoides aitchisonii fruit body which is safe and cheap, harvested constantly year-round by artificial cultivation, with equal quality, and useful for prevention and/or amelioration of symptom of hypertension caused by angiotensin I converting enzyme or the like. The invention also includes foods or beverages containing the pharmacological compositions, and methods of preventing or treating hypertension by administration of the composition.

    摘要翻译： 一种药物组合物，其包含具有降压活性成分的成分，该成分是安全且便宜的，通过人工培养全年不断收获，质量相同，可用于预防和/或改善由血管紧张素引起的高血压症状 I转化酶等。 本发明还包括含有药物组合物的食品或饮料，以及通过施用组合物预防或治疗高血压的方法。

    Prevention of infectious diseases with hsp70-peptide complexes
    10.
    发明授权
    Prevention of infectious diseases with hsp70-peptide complexes 失效
    用hsp70肽复合物预防传染病

    公开(公告)号：US06399069B1

    公开(公告)日：2002-06-04

    申请号：US09439684

    申请日：1999-11-15

    申请人： Pramod K. Srivastava ,  Rajiv Y. Chandawarkar

    发明人： Pramod K. Srivastava ,  Rajiv Y. Chandawarkar

    IPC分类号： A61K39385

    CPC分类号： A61K39/0011 ,  A61K2039/6043 ,  A61K2039/622 ,  Y02A50/466

    摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.1 to 9.0 micrograms for complexes comprising hsp70, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96.

    摘要翻译： 本发明涉及引发免疫应答和预防和治疗原发性和转移性肿瘤性疾病和传染病的方法和组合物。 本发明的方法包括施用包含有效量的复合物的组合物，其中复合物基本上由非共价结合于抗原分子的热休克蛋白（hsp）组成。 任选地，所述方法还包括施用用非共价结合于抗原分子的hsps复合物致敏的抗原呈递细胞。 本文所用的“抗原分子”是指hsps与体内内源性相关的肽以及外源性抗原/免疫原（即hsps在体内不复合）或其抗原/免疫原性片段及其衍生物。 在优选的实施方案中，复合物是个体自体的。 在一个具体实施方案中，对于包含hsp70,5-449微克对于hsp90和对于gp96为0.1至9.0微克的复合物，复合物的有效量在0.1至9.0微克范围内。